On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant for postmenopausal, non-pregnant women and adult men with…
On January 27, 2023, the U.S. Food and Drug Administration approved Pirtobrutinib for adult patients with histologically confirmed relapsed or…
On January 26, 2023, the U.S. Food and Drug Administration approved Pembrolizumab for patients with resectable, stage IB (≥4cm)-IIIA (as…
On January 19, 2023, the U.S. Food and Drug Administration granted accelerated approval to Tucatinib plus Trastuzumab for adult patients…